Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
56.10%
Operating Margin
1.13%
Net Margin
-38.33%
Efficiency Metrics
Revenue per Expense Ratio
1.04
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
37.49%
Income Tax Rate
49,200,000.0%
EPS
-1.2200000000
Balance Sheet Analysis
Current Ratio
1.47
Cash Ratio
0.34
Working Capital
$38.86M
Debt to Equity
1.63
Debt to Assets
57.20%
Equity Ratio
35.10%
Cash Flow Analysis
Operating Cash Flow Ratio
16.27%
Free Cash Flow Ratio
11.82%
CapEx to Revenue
4.45%
Dividends Paid
$5.12M
Stock Buybacks
$682.00K
Total Shareholder Returns
$5.81M
Cash Position Change
14.54%
Key Takeaways (2023 FY)
Revenue declined by 21.170475863196%, indicating potential market challenges
Maintained positive net income growth despite revenue changes
Increased dividend payments by 8,221.86%
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
-21.17%
Net Income
4.38%
EPS
0.81%
Operating Income
-88.72%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
-20.82%
Operating Cash Flow
-31.47%
Free Cash Flow
139.42%
Balance Sheet Health
Assets
-17.34%
Debt
-2.63%
Book Value per Share
-32.48%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
8,221.86%
Shares Outstanding
0.92%
Long Term Trends
3Y Revenue/Share
-11.95%
5Y Revenue/Share
-42.18%
3Y Dividend/Share
-91.65%
5Y Dividend/Share
-94.03%